View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 20, 2020

UK enters supply agreement for Pfizer and BioNTech’s Covid-19 vaccine

The UK Government has signed an agreement with Pfizer and BioNTech for the supply of 30 million doses of the companies' mRNA-based Covid-19 vaccine candidate, BNT162.

The UK Government has signed an agreement with Pfizer and BioNTech for the supply of 30 million doses of the companies’ mRNA-based Covid-19 vaccine candidate, BNT162.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Neither company divulged financial details of the deal, but the terms were said to be contingent on the delivery timing and the volume of doses.

Based on BioNTech’s mRNA technology, BNT162 sss Pfizer’s expertise in vaccine development and manufacturing. The vaccine candidate is currently undergoing clinical studies.

BioNTech CEO and co-founder Ugur Sahin said: “This agreement is part of our commitment to address the pandemic by creating a global supply.

“We are in advanced discussions with multiple other government bodies and hope to announce additional supply agreements soon. Our goal remains to bring a safe and effective Covid-19 vaccine to many people around the world, as quickly as we can.”

The Pfizer and BioNTech collaboration is working on at least four experimental vaccines against Covid-19. Two of these candidates, BNT162b1 and BNT162b2, secured the US Food and Drug Administration (FDA) fast track designation.

If positive data is obtained in ongoing trials, the partners intend to file for conditional marketing authorisation or other types of regulatory approval as early as October.

Currently, the companies anticipate manufacturing of up to 100 million doses globally by the end of this year, and potentially more than 1.3 billion doses by the end of next year, subject to final dose selection from the trial.

In addition to this deal, the UK Government has entered into a similar agreement with French company Valneva, which will supply up to 100 million doses of its potential Covid-19 vaccine.

The vaccine candidate will be produced at Valneva’s facilities in Livingston, Scotland.

As part of the agreement, the UK will contribute to costs associated with clinical trials in the country and is negotiating funding to expand Valneva’s facility in Scotland.

In May, the government signed a supply agreement with AstraZeneca for the Oxford Covid-19 vaccine candidate.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology